Compare PULM & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PULM | JAGX |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.9M |
| IPO Year | 2013 | 2014 |
| Metric | PULM | JAGX |
|---|---|---|
| Price | $1.36 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 10.0K | ★ 173.3K |
| Earning Date | 05-14-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.18 | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $7,910,000.00 | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.16 | $0.22 |
| 52 Week High | $5.50 | $8.00 |
| Indicator | PULM | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 28.51 |
| Support Level | $1.21 | $0.60 |
| Resistance Level | $1.44 | $1.04 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 11.54 | 2.47 |
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.